These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 18347632

  • 1. Paracentesis before intravitreal injection of bevacizumab.
    Tsui YP, Chiang CC, Tsai YY.
    Can J Ophthalmol; 2008 Apr; 43(2):239; author reply 239-40. PubMed ID: 18347632
    [No Abstract] [Full Text] [Related]

  • 2. Short-term intraocular pressure changes after intravitreal injection of bevacizumab.
    Hollands H, Wong J, Bruen R, Campbell RJ, Sharma S, Gale J.
    Can J Ophthalmol; 2007 Dec; 42(6):807-11. PubMed ID: 18026202
    [Abstract] [Full Text] [Related]

  • 3. Necessity of paracentesis before or after intravitreal injection of bevacizumab.
    Huang WC, Lin JM, Chiang CC, Tsai YY.
    Arch Ophthalmol; 2008 Sep; 126(9):1314-5; author reply 1315. PubMed ID: 18779502
    [No Abstract] [Full Text] [Related]

  • 4. Bilateral simultaneous intravitreal injections in the office setting.
    Bakri SJ, Risco M, Edwards AO, Pulido JS.
    Am J Ophthalmol; 2009 Jul; 148(1):66-9.e1. PubMed ID: 19403114
    [Abstract] [Full Text] [Related]

  • 5. Re: Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin).
    Utman SA, Dhillon B.
    Retina; 2008 Apr; 28(4):667; author reply 667-8. PubMed ID: 18398378
    [No Abstract] [Full Text] [Related]

  • 6. Bevacizumab local complications.
    Gordon-Angelozzi M, Velez-Montoya R, Fromow-Guerra J, García-Aguirre G, Guerrero-Naranjo JL, Quiroz-Mercado H, Morales-Cantón V.
    Ophthalmology; 2009 Nov; 116(11):2264.e1-3. PubMed ID: 19883862
    [No Abstract] [Full Text] [Related]

  • 7. Assessment of anterior chamber inflammation after intravitreal bevacizumab injection in different ocular exudative diseases.
    Yeniad B, Ayranci O, Tuncer S, Kir N, Ovali T, Tugal-Tutkun I, Akarcay K.
    Eur J Ophthalmol; 2011 Nov; 21(2):156-61. PubMed ID: 20658459
    [Abstract] [Full Text] [Related]

  • 8. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF, Fromow-Guerra J, Sanchez JG, Maia M, Berrocal MH, Wu L, Saravia MJ, Costa RA, Pan-American Collaborative Retina Study Group.
    Retina; 2008 Nov; 28(10):1387-94. PubMed ID: 18827735
    [Abstract] [Full Text] [Related]

  • 9. Intravitreal bevacizumab.
    Lucas RS, McKee HD, Lee LR.
    Ophthalmology; 2007 Feb; 114(2):400; author reply 400-1. PubMed ID: 17270701
    [No Abstract] [Full Text] [Related]

  • 10. Combined cataract extraction and intravitreal bevacizumab in eyes with choroidal neovascularization resulting from age-related macular degeneration.
    Furino C, Ferrara A, Cardascia N, Besozzi G, Alessio G, Sborgia L, Boscia F.
    J Cataract Refract Surg; 2009 Sep; 35(9):1518-22. PubMed ID: 19683147
    [Abstract] [Full Text] [Related]

  • 11. Intravitreal bevacizumab for parapapillary choroidal neovascularization due to exudative age-related macular degeneration.
    Jonas JB, Tao Y, Rensch F.
    Acta Ophthalmol; 2011 Feb; 89(1):e105-7. PubMed ID: 20064119
    [No Abstract] [Full Text] [Related]

  • 12. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
    Melamud A, Stinnett S, Fekrat S.
    Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema.
    Kumar V, Ghosh B, Raina UK, Goel N.
    Acta Ophthalmol; 2010 Mar; 88(2):e3; author reply e4. PubMed ID: 19549100
    [No Abstract] [Full Text] [Related]

  • 14. Controversies in the treatment of wet age-related macular degeneration.
    Moreno SF, Paloma JB.
    Am J Ophthalmol; 2008 May; 145(5):937; author reply 938. PubMed ID: 18435977
    [No Abstract] [Full Text] [Related]

  • 15. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A.
    Retina; 2007 May; 27(4):432-8. PubMed ID: 17420694
    [Abstract] [Full Text] [Related]

  • 16. Diffuse diabetic macular oedema treated with intravitreal bevacizumab or triamcinolone acetonide.
    Rensch F, Spandau UH, Wickenhäuser A, Jonas JB.
    Acta Ophthalmol; 2010 Mar; 88(2):e36-7. PubMed ID: 19210330
    [No Abstract] [Full Text] [Related]

  • 17. Intravitreal bevacizumab (Avastin) for primary treatment of diabetic macular oedema.
    Ozkiriş A.
    Eye (Lond); 2009 Mar; 23(3):616-20. PubMed ID: 18437176
    [Abstract] [Full Text] [Related]

  • 18. The as-needed treatment strategy for choroidal neovascularization: a feedback-based treatment system.
    Spaide RF.
    Am J Ophthalmol; 2009 Jul; 148(1):1-3. PubMed ID: 19540983
    [No Abstract] [Full Text] [Related]

  • 19. Case of anterior uveitis after intravitreal injection of bevacizumab.
    Pieramici DJ, Avery RL, Castellarin AA, Nasir MA, Rabena M.
    Retina; 2006 Sep; 26(7):841-2. PubMed ID: 16963867
    [No Abstract] [Full Text] [Related]

  • 20. Anti-VEGF therapy: riding the wave of change.
    Hunyor AP.
    Clin Exp Ophthalmol; 2008 Jul; 36(5):401-2. PubMed ID: 18925912
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.